Αρχική World News New Immunotherapy Option Approved for Cervical Cancer, Rare Lymphoma

New Immunotherapy Option Approved for Cervical Cancer, Rare Lymphoma

August 2, 2018, by NCI Staff

Metastatic cervical cancer cells.

Credit: National Cancer Institute

In June, the Food and Drug Administration (FDA) further expanded the approved uses of the immunotherapy drug pembrolizumab (Keytruda). The two recent approvals cover the use of pembrolizumab for some women with advanced cervical cancer and for adults and children with relapsed or treatment-resistant primary mediastinal large B-cell lymphoma (PMBCL), a rare type of aggressive non-Hodgkin lymphoma.

Both actions by FDA were accelerated approvals, meaning further studies are needed to confirm the drug’s clinical benefit in patients with these cancers.

Pembrolizumab is a type of immunotherapy called an immune checkpoint inhibitor. It works by blocking the binding of PD-1, a protein expressed on cytotoxic T cells, to the PD-L1 protein expressed on some cancer cells, an interaction that acts as a brake on the immune system and prevents T cells from attacking the cancer.

First Approval of a PD-1 Inhibitor for Cervical Cancer

On June 12, FDA approved pembrolizumab to treat women with cervical cancer that has recurred or spread (metastasized) to other parts of the body and gotten worse during or after chemotherapy. The approval makes pembrolizumab the first immune checkpoint inhibitor approved to treat cervical cancer.

Under the approval, patients’ tumors must express PD-L1, as determined by an FDA-approved laboratory test. FDA simultaneously approved the PD-L1 IHC 22C3 pharmDx test (manufactured by Dako North America, Inc.), as a companion diagnostic test for women with cervical cancer.

The accelerated approval was based on results from a single cohort of 98 women with cervical cancer who were enrolled in an ongoing phase 2 clinical trial of pembrolizumab for the treatment of several cancer types. The trial, called Keynote-158, is sponsored by Merck, the drug’s manufacturer.

Of the 98 women, 77 had tumors that expressed PD-L1. Two of these women had their tumors disappear completely (complete responses) and nine had their tumors shrink by 30% or more (partial responses), for an overall response rate of 14.3%. In 10 of the 11 women who responded to pembrolizumab, the responses lasted 6 months or longer, and after nearly 12 months of follow-up, the median duration of response had not been reached. None of the women with PD-L1–negative tumors responded to pembrolizumab.

Nearly 40% of the women experienced serious side effects, including anemia (7%), fistula (4%), infection (4%), or hemorrhage (4%), and 8% of the patients had to stop treatment because of them. The most common side effects included fatigue, pain, nausea and vomiting, and difficulty breathing (dyspnea).

The current standard of care for women with cervical cancer that has recurred or metastasized after previous treatment is chemotherapy in combination with bevacizumab (Avastin). FDA approved the combination regimen in 2014 based on results of an sponsored randomized phase 3 trial showing a 3.7-month improvement in median overall survival with the addition of bevacizumab to chemotherapy.

The clinical trials that led to the approvals of bevacizumab and pembrolizumab for cervical cancer that recurs or spreads and worsens during or after chemotherapy had different designs and goals, so “it’s not possible to compare the two regimens given the data currently available,” said Elise Kohn, M.D., Gynecologic Cancer Therapeutics Lead in NCI’s Cancer Therapy Evaluation Program.

“We now have two very different approved therapeutic options for these patients,” she said, “so patients should discuss the pros and cons of each regimen with their physicians before deciding on their treatment.”

Dr. Kohn stressed that patients and clinicians need to weigh the risks of side effects when considering the treatment options.

“Although the patterns of toxicity are different, they are not insignificant for either option,” she explained.

New Treatment Option for Rare Lymphoma

On June 13, FDA approved pembrolizumab for the treatment of adult and pediatric patients with PMBCL that is resistant to available treatments (refractory) or returned following treatment with two prior therapies.

The accelerated approval was based on results from a multicenter single-arm phase 2 trial called Keynote-170. The trial, sponsored by Merck, included 53 patients between the ages of 20 and 61 with relapsed or refractory PMBCL.

Although there were no children in the trial, “efficacy for pediatric patients with PMBCL was extrapolated from the results in the adult PMBCL population,” according to a Merck news release, and safety was determined based on “a study of 40 pediatric patients with advanced melanoma, lymphoma, or PD-L1–positive advanced, relapsed, or refractory solid tumors” who were treated with pembrolizumab.

The overall response rate  in the Keynote-170 trial was 45%, with 11% of patients achieving a complete response and 34% experiencing a partial response. At an average follow-up of nearly 10 months, the median duration of response had not yet been reached.

In its approval notice, FDA stated that pembrolizumab should not be used in patients who have an urgent need for surgery to reduce a PMBCL mass that may be compressing a major blood vessel or other critical structure within the mediastinum.

The most common side effects of pembrolizumab in the Keynote-170 trial included musculoskeletal pain, upper respiratory tract infection, fever, fatigue, and dyspnea. Serious side effects occurred in 26% of patients, causing 15% to interrupt therapy and 8% to discontinue treatment with pembrolizumab entirely. Twenty-five percent of patients had side effects that required treatment with corticosteroids.

“In the short follow-up thus far, there haven’t been signs of increased toxicity compared to other trials of PD-1 inhibitors,” said Mark Roschewski, M.D., of the Lymphoid Malignancies Branch in NCI’s Center for Cancer Research. “But PMBCL patients are often young and female, so longer follow-up will be important for these patients because their lifetime risk of developing autoimmune diseases is much higher” than older patients treated with PD-1 inhibitors, he emphasized. 

The distinction between patients with refractory PMBCL after first-line therapy and those who have relapsed or still have refractory disease following two previous lines of therapy is important, said Dr. Roschewski. Patients who have not been cured despite two previous lines of therapy—the patients covered by this approval—have a very poor prognosis. 

“These patients need better therapies,” he said. “Now that we have an approved drug in PMBCL, it opens the possibility of combination therapy studies, such as pembrolizumab and CAR T-cell therapy, for example.”



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Overall Breast Cancer Incidence Down Since 1999, Rates Increase for Women Under 40

U.S. breast cancer death rates decreased by about 1% per year between 2013 and 2018. What were the new case rates during that same...

Impressive Responses to PD-1 Blockade in a Large Cohort of Children and Young Adults with Recurrent/Progressive Germline DNA Replication Repair-Deficient Cancers

A large, observational, registry-based study that leveraged systematically collected data gathered both retrospectively and prospectively through the International Replication Repair Deficiency Consortium reveals impressive...

2-Year-Boy Is So Excited To See Himself In Disney’s ‘Encanto’

The importance of representation in media has been a growing topic of concern, and companies have responded by adding more diversity to their characters,...

Man Walks Entire Continent To Spread Awareness About Mental Health & Suicide Prevention

Matthew Fennell is walking over 3,000 miles across Australia for an important cause and one that is near and dear to his heart. Last year,...

Boy Battling Cancer Becomes Honorary Police Officer, Sworn In To 45 Agencies

At just ten years old, Devarjaye “DJ” Daniel has already been through more than most people go through in their entire lives. DJ has been...

Paclitaxel and Carboplatin Not Inferior When Compared with Paclitaxel and Ifosfamide for the Treatment of Patients with Uterine Carcinosarcoma

With regard to overall survival (OS), paclitaxel and carboplatin was not inferior and demonstrated improved progression-free survival (PFS) when compared with paclitaxel and ifosfamide...